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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.013We recently deﬁned molecular subtypes of urothelial carcinomas according to whole genome gene
expression. Herein we describe molecular pathologic characterization of the subtypes using 20 genes
and IHC of 237 tumors. In addition to differences in expression levels, the subtypes show important
differences in stratiﬁcation of protein expression. The selected genes included biological features
central to bladder cancer biology, eg, cell cycle activity, cellular architecture, cell-cell interactions, and
key receptor tyrosine kinases. We show that the urobasal (Uro) A subtype shares features with normal
urothelium such as keratin 5 (KRT5), P-cadherin (P-Cad), and epidermal growth factor receptor (EGFR)
expression conﬁned to basal cells, and cell cycle activity (CCNB1) restricted to the tumor-stroma
interface. In contrast, the squamous cell cancerelike (SCCL) subtype uniformly expresses KRT5, P-Cad,
EGFR, KRT14, and cell cycle genes throughout the tumor parenchyma. The genomically unstable subtype
shows proliferation throughout the tumor parenchyma and high ERBB2 and E-Cad expression but
absence of KRT5, P-Cad, and EGFR expression. UroB tumors demonstrate features shared by both UroA
and SCCL subtypes. A major transition in tumor progression seems to be loss of dependency of stromal
interaction for proliferation. We present a simple IHC/histology-based classiﬁer that is easy to
implement as a standard pathologic evaluation to differentiate the three major subtypes: urobasal,
genomically unstable, and SCCL. These three major subtypes exhibit important prognostic differences.
(Am J Pathol 2013, 183: 681e691; http://dx.doi.org/10.1016/j.ajpath.2013.05.013)Supported by The Swedish Cancer Society, The Swedish Research
Council, The Nilsson Cancer Foundation, and BioCARE.Assessment of urothelial carcinoma for clinical intervention
is determined using standard pathologic variables. For
example, the European Organisation for Research and
Treatment of Cancer risk tables include tumor grade, tumor
stage, and presence or absence of carcinoma in situ, com-
plemented by information on previous recurrence rate, tumor
diameter, and number of tumors. Although these tables are
efﬁcient in controlled investigations, routine pathologic
assessments are subjected to large interobserver variability,
making clinical decisions uncertain.1 Furthermore, to enable
unambiguous assessment of stage, for example, high-quality
transurethral resection of bladder tumor samples that include
muscle tissue is necessary. However, pathologic assessment
alone is not sufﬁcient to capture the underlying heterogeneity
believed to exist among urothelial carcinomas such as T1
tumors. Accumulating molecular data support the existence
of two broad pathogenetic subtypes of urothelial carcinomastigative Pathology.
.that largely correspond to nonemuscle-invasive and muscle-
invasive tumors, respectively.2 Nonemuscle-invasive
tumors typically exhibit frequent ﬁbroblast growth factor
receptor 3 (FGFR3) and PI3-kinase catacytic subunit
a (PIK3CA) mutations, few chromosomal changes, and low
mitotic or MKI67 (antigen Ki-67) activity. The more
aggressive muscle-invasive tumors typically exhibit tumor
protein p53 (TP53) mutations, high proliferative activity, and
signs of genomic instability. Using gene expression proﬁling,
we have recently shown that urothelial carcinoma may be
divided into two major molecular subtypes, MS1 and MS2.3
In a subsequent study, and using a larger set of tumors,
further divisions were possible, resulting in a molecular
taxonomy with four subtypes of urothelial carcinoma with
Sjödahl et aldistinct molecular properties: urobasal A (UroA), urobasal B
(UroB), squamous cancer cellelike (SSCL), and genomi-
cally unstable (GU) tumors.4 The subtypes demonstrate
distinct survival patterns in which UroA tumors are associ-
ated with a good prognosis, and UroB and SCCL tumors with
the worst outcome. The suggested molecular classiﬁcation
shows only a moderate overlap with pathologic grade and
stage. For example, at the molecular level, T1G3 tumors were
classiﬁed as any of the four subtypes and muscle-invasive
tumors as UroB, SCCL, or GU. Hence, our molecular
taxonomy based on mRNA gene expression proﬁling reﬁnes
the classiﬁcation of urothelial carcinoma into subtypes with
potential clinical effect. In the present investigation, we
applied a large number of immunohistochemistry (IHC)
markers to a cohort previously classiﬁed by available gene
expression array proﬁling data and made a thorough molec-
ular pathologic characterization of the suggested subtypes.
Moreover, we demonstrated that a simple classiﬁer that
combines markers for basal cell status (KRT5, or cytokeratin
5) and proliferation (CCNB1, or cyclin B1), along with two
histologic or morphologic variables, reproduced the three
major molecular subtypes of urothelial carcinoma: UroA and
UroB, GU, and SCCL.
Materials and Methods
Patient and Sample Selection
Tumor biopsy samples from 237 patients with urothelial
carcinoma diagnosed at the Southern Sweden Health Care
Region between 2001 and 2009 were included. From an
original cohort of 308 cases previously analyzed by us using
whole genome expression analysis,4 we excluded 42 cases of
the inﬁltrated subtype and 29 for which material for tissue
microarray analysis (TMA) was not available. Patient and
tumor data are given in Supplemental Table S1. The inves-
tigation was approved by the Regional Ethics Committee
(ﬁrst received date February 25, 2010; ref. No. 2010/5).
Tissue Microarrays and IHC
TMA blocks were constructed from 1.0 mm punches of
formalin-ﬁxed parafﬁn-embedded urothelial carcinoma
specimens using a manual arrayer (Pathology Devices, Inc.,
Westminster, MD). Except in six cases, two cores per
sample were included. From TMA blocks, tissue sections (3
to 4 mm thick) were mounted on glass slides (SuperFrost
Plus; Gerhard Menzel GmbH, Braunschweig, Germany),
dried at room temperature, and incubated for 2 hours at
60C. Slides were pretreated using the PT Link Kit (pH 9)
(Dako AS, Glostrup, Denmark). Antibody staining was
performed using an Autostainer Plus (Dako). Standard
incubation time was 30 minutes. Visualization of stained
slides was performed using EnVision FLEX K8010 (Dako).
Slides were counterstained with Mayer’s hematoxylin for 2
minutes, and then were dehydrated.682Antibodies and IHC Evaluations
Antibodies used, product numbers, vendors, and dilutions
for each primary antibody are given in Table 1. Cores were
evaluated blinded as digitalized image ﬁles (ScanScope;
Aperio, Vista, CA) by two independent investigators (G.S.
and M.H.). For CCND1 (cyclin D1), CCNE1 (cyclin E1),
CDH1 [E-cadherin (E-Cad)], epidermal growth factor
receptor (EGFR), ERBB2 (Her-2), FGFR3, KRT5, KRT6
(cytokeratin 6), KRT14 (cytokeratin 14), KRT20 (cytoker-
atin 20), CDH3 [P-cadherin (P-Cad)], CDH2 [N-cadherin
(N-Cad)], DSC2/3 (desmocollin 2/3), E2F3 (E2F tran-
scription factor 3), RB1 (retinoblastoma 1), cyclin-
dependent kinase inhibitor 2A, isoform 1 (CDKN2A), and
uroplakin 3 (UPK3), the labeling intensity was assigned as
no, low, moderate, or high expression (0 to 3, respectively).
Tumor cell score (TCS) was deﬁned as intensity multiplied
by the fraction of positive tumor cells in 10% intervals. For
CCNB1, MKI67, and tumor protein p63 (TP63), only the
fraction of positive tumor cell nuclei was recorded. Because
intensity cutoffs must be set individually for each marker,
we have shown representative images in the Supplemental
Appendix. For each case and each antibody, the mean
TCS of core pairs from the same sample was calculated, and
all IHC data are given in Supplemental Table S2. The
number of cases with high difference between core pairs in
intensity (DI 2) or tumor cell score (DTCS 2) was used
as a measure of concordance and is given in Table 1. The
number of core pairs evaluated for each marker ranged from
194 to 217. Downloadable IHC images in PDF format for
all cases are available on request.
Histopathologic Evaluation
Tumor stage and grade were evaluated using the World
Health Organization 1999 classiﬁcation system. Three types
of histologic annotations were made: invasive growth
pattern, urothelial-like or not, and histologic variant.
Examples of each type of histologic annotation are shown in
Supplemental Figure S1. Growth patterns in invasive tumors
were recorded as nodular, trabecular, or inﬁltrative using the
deﬁnitions provided by Jimenez et al5 (Supplemental
Figure S1, AeC) The term urothelial-like was used to
denote tumors with stroma separated from the tumor cells
by a smooth undisrupted basal interface, an overall orga-
nized tumor parenchyma, and nuclei of relatively similar
form and size (Supplemental Figure S1D). The annotation
urothelial-like was given to tumors that fulﬁlled all of these
criteria. a-Smooth muscle actin (ACTA2) staining was used
to evaluate the integrity of the tumor-stroma interface. The
presence of histologic variants was recorded as signs of
squamous and glandular differentiation (Supplemental
Figure S1, F and G).6e8 Signs of squamous differentiation
considered included polygonal cell shape; distinct cell
borders; high cytoplasm/nucleus ratio; presence of desmo-
somes (aided by DSC2/3 staining), keratinization, visible asajp.amjpathol.org - The American Journal of Pathology
Table 1 Antibody Information, Concordance between Duplicate Cores, and Correlation With mRNA Levels
Marker Catalog No. Vendor Dilution DI 2* DTCS 2y TCS-GEX rz Pz
CCNB1 1495-1 Epitomics 1:100 NA 7 (3.3) 0.6 3.1  1025
CCND1 M3635 Dako 1:100 15 (7.0) 1 (0.5) 0.56 1.4  1021
CCNE1 NCL-CYCLIN E Leica 1:60 26 (12.4) 2 (1.0) 0.63 9.5  1028
CDH1 M3612 Dako 1:200 16 (7.5) 11 (5.1) 0.28 6.7  106
CDH2 33-3900 Invitrogen 1:100 12 (5.5) 3 (1.4) 0.54 1.2  1019
CDH3 #610228 BD Biosciences 1:200 21 (10.0) 7 (3.3) 0.46 5.3  1014
CDKN2A #550834 BD Biosciences 1:50 9 (4.2) 7 (3.3) 0.56 6.3  1022
DSC2/3 C228807 LifeSpan 1:35 2 (1.0) 2 (1.0) 0.4 6.9  1011
E2F3 MS-1063 Lab Vision 1:80 15 (7.4) 0 (0) 0.45 9.2  1014
EGFR 790-2991 Ventana RTU 19 (8.8) 10 (4.6) 0.47 4.5  1015
ERBB2 790-2991 Ventana RTU 7 (3.3) 6 (2.8) 0.49 5.2  1016
FGFR3 #4574 Cell Signaling 1:40 10 (4.8) 10 (4.8) 0.65 1.6  1030
KRT14 MS-115 Lab Vision 1:200 14 (6.6) 2 (0.9) 0.64 1.1  1029
KRT20 M7019 Dako 1:500 29 (14.4) 19 (9.5) 0.61 8.8  1026
KRT5 RM-2106 Lab Vision 1:200 37 (17.6) 5 (2.4) 0.72 1.6  1039
KRT6 MS-766 Lab Vision 1:200 10 (4.7) 9 (4.2) 0.42 3.8  1012
MKI67 RM-9106 Lab Vision 1:500 NA 14 (6.8) 0.62 1.0  1026
RB1 #9309 Cell Signaling 1:100 8 (3.8) 4 (1.9) 0.44 4.0  1013
TP63 IMG-80212 Imgenex 1:100 NA 29 (13.6) 0.73 1.9  1041
UPK3 AIB-30180 Nordic Biosite 1:20 36 (17.2) 4 (1.9) 0.19 0.0013
*Number and percentage of tumors showing a large difference in intensity between cores from the same sample.
yNumber and percentage of tumors showing a large difference in TCS between cores from the same sample.
zCorrelation between TCS and relative mRNA levels indicated by Pearson r and corresponding P values.
NA, not available.
Classiﬁcation of Urothelial Carcinomaintracellular or extracellular material with bright homoge-
neous staining (aided by KRT5 and KRT14 staining);
presence of apoptotic ink-cells; and brightly stained nuclei
(H&E) with clearly visible nucleoli. Signs of glandular
differentiation considered included tubular structures and
columnar cells, glandular spaces within the tumor mass,
mucin-containing cells, and decreased thickness of cell
layers. The group of SCCL tumors was originally deﬁned by
their gene expression proﬁle, which shows high expression
of genes involved in keratinization characteristic of normal
squamous tissue. Most SCCL tumors also showed histologic
signs of squamous differentiation in whole tissue sections.4
Tumor Classiﬁcation
For potential variables to include in a classiﬁer we considered
IHC markers with strong distinctive staining (CCNB1,
CCND1, CDH1 (E-Cad), CDH3 (P-Cad), CDKN2A, DSC2/
3, EGFR, ERBB2, FGFR3, KRT5, KRT14, MKI67, and
TP63), along with sex, tumor grade, urothelial-like histologic
ﬁndings, invasive growth pattern, and squamous or glandular
differentiation. We also considered marker stratiﬁcation in
relation to tumor stroma. The classiﬁer was constructed in
a treewise fashion starting with the division urobasal versus
GU/SCCL, and then subdivisions for UroA versus UroB and
GU versus SCCL. For reliable use across laboratories, we
decided to dichotomize all numerical features to 0 or 1 using
a threshold. Optimal cutoffs were determined via receiver
operating characteristic analyses using the R packages
ROCR9 and rocc10. For categorical variables, we evaluatedThe American Journal of Pathology - ajp.amjpathol.orgall possible dichotomization options, and values were set at
0 or 1. Dichotomized variables were then ranked by associ-
ation to true class measured using the Fisher exact test, and
the top ranked feature was selected. Additional features were
added if the P value from multivariate logistic regression
(true class dependent on features) added signiﬁcant infor-
mation to the already selected features (P Z 0.001). Only
three IHC markers were allowed, and ﬁve features overall,
restricting the feature selection method to few markers that
carry independent information. The classiﬁcation score was
deﬁned as the sum of feature values for a division and ranged
from 0 to the number of features included. Receiver operating
characteristic analyses were used to determine the best clas-
siﬁcation score cutoff in each division. A new sample is
classiﬁed along the classiﬁcation tree as being above or
below the classiﬁcation score cutoff in each division (for full
classiﬁer structure, see Supplemental Figure S2). To estimate
the accuracy of our classiﬁcation system, we used leave-one-
out cross-validation comparing classiﬁcations with the true
sample classes as determined via previous genomewide gene
expression analyses.4 We then assessed the effect of addi-
tional makers on classiﬁcation accuracy. To include more
markers, we relaxed the P value from multivariate logistic
regression in feature selection from PZ 0.001 to PZ 0.01
and P Z 0.05. In the ﬁrst division, CCND1 (classiﬁer B,
P Z 0.01) and MKI67 (classiﬁer C, P Z 0.05) were
included. For the division of SCCL versus GU, no marker
provided additional information in the extended models.
Classiﬁcation accuracy in leave-one-out cross-validation was
0.884, 0.879, and 0.879 for the original classiﬁer, classiﬁer B,683
Figure 1 A: Heat map of mRNA expression
levels for 19 of 20 selected genes. Heat map is
based on data published by Sjödahl et al4 B: Heat
map of relative IHC TCS or fractions of positive
cells, both standardized across cases. C: Distribu-
tion of pathologic stage, grade, urothelial-like
growth pattern, and signs of squamous and glan-
dular differentiation in molecular subytpes. For
stage and grade, respectively, green bars indicate
Ta or G1 tumors, blue bars indicate T1 or G2
tumors, and red bars indicate T2 or G3 tumors.
Black bars indicate urothelial-like growth pattern
and signs of squamous or glandular differentia-
tion. Gray bars represent missing data. D: Expres-
sion of FGFR3/CCND1 and E2F3/RB1 genomic
circuits across samples. Casewise scores for the
respective circuits are calculated as described in
Material and Methods.
Sjödahl et aland classiﬁer C, respectively. Hence, adding more markers
resulted in similar classiﬁer performance.Statistical Analysis
The Fisher exact test was used to test differences in propor-
tions of categorical data. Differences in intensity and TCS
were evaluated using U tests. The urothelial carcinomae
speciﬁc genomic circuits were adapted from Lindgren et al.11
Genomic circuit scores were calculated as FGFR3/CCND1
circuitZ TCSFGFR3þ TCSCCND1 TCSP16, and E2F3/RB1
circuit Z TCSE2F3 þ TCSP16  TCSRB1. For clinical asso-
ciations, Kaplan-Meier analyses and Cox regression with the
log-rank test for signiﬁcance were used.Results
IHC Markers
We constructed tissue microarrays from 237 urothelial
carcinomas previously classiﬁed into the four molecular
subtypes UroA (nZ 118 ), UroB (nZ 20 ), SCCL (nZ 25),
and GU (nZ 74) using gene expression proﬁling.4 Twenty
genes were selected as possible class-deﬁning IHC markers
(Figure 1A). The intensity scoring showed overall good
concordance between core pairs from the same biopsy
sample (Table 1). However, because the TCS showed better
concordance, this measure was primarily used in the subse-
quent analyses. Correlations between mRNA expression and
TCS ranged between 0.42 and 0.73, with CDH1 (E-Cad) and
UPK3 as outliers (r < 0.30) (Table 1). Overall, the IHC684results were in good concordance with those obtained via
mRNA gene expression analyses (Figure 1, A and B).
Molecular Pathologic Characterization
UroA Tumors
Most UroA tumors were nonemuscle-invasive (92%), of low
grade (G1 or G2) (86%), and with urothelial-like histologic
features (86%) (Table 2 and Figure 1C). FGFR3 showed
homogeneous staining in all tumor cells in 92% of UroA
samples. The most luminal cell layer, when present in the
TMA cores, was consistently negative for TP63, whereas
intermediate and basal cell layers were positive (Figure 2A).
CCND1 showed nuclear staining and ranged from being
expressed in the suprabasal cell layer only to including all
tumor cells, resulting in strong but variable CCND1
expression. A total of 96% of tumors were positive for
CCND1 expression. In general, the fractions of CCND1þ
cells were larger than for CCNB1þ or MKI67þ cells.
KRT5 expression was observed in 106 tumors (91%) and
was restricted to the basal cell layer in 49% of tumors
(Figure 2A). An almost identical pattern with positive cells
conﬁned to the basal cell layer was noted for CDH3 (P-
Cad). In contrast, CDH1 (E-Cad) expression was detected in
all cell layers and in 98% of UroA tumors. CDH2 (N-Cad)
expression was absent in 75% of UroA tumors and was
expressed at very low levels when positive. Thus, cadherin-
mediated epithelial cell-cell adhesion is not altered in UroA
tumors compared with normal urothelium. CCNB1 expres-
sion was limited to the suprabasal cell layer in most UroA
tumors (Figure 2A). CCNB1þ cells were typically elongated
and in contact with the tumor-stroma interface. MKI67ajp.amjpathol.org - The American Journal of Pathology
Table 2 Tumor Pathologic Characteristics and Growth Patterns
Variable UroA* (n Z 118) UroB* (n Z 20) SCCL* (n Z 25) GU* (n Z 74)
Stagey
Ta 78 (66) 4 (20) 2 (8) 8 (11)
T1 31 (26) 6 (30) 1 (4) 40 (54)
T2 8 (7) 9 (45) 22 (88) 26 (35)
Tx 1 (1) 1 (5) 0 0
Gradey
G1 33 (28) 0 1 (4) 1 (1)
G2 68 (58) 9 (45) 1 (4) 10 (14)
G3 17 (14) 11 (55) 23 (92) 63 (85)
Growth patternz
Urothelial-like 99/115 (86) 11/18 (61) 1/25 (4) 6/68 (9)
Not urothelial-like 16/115 (14) 7/18 (39) 24/25 (96) 62/68 (91)
Inﬁltrative 1/116 (1) 4/20 (20) 10/25 (40) 18/74 (24)
Nodular 2/116 (2) 0 1/25 (4) 5/74 (7)
Trabecular 0 2/20 (10) 9/25 (36) 11/74 (15)
Histologic variantz
Squamous 4/116 (3) 5/20 (25) 11/25 (44) 3/74 (4)
Glandular 0 0 0 8/74 (11)
Values are given as No. (%).
*Molecular subclass according to whole genome gene expression.4
yDetermined via pathologic evaluation of parafﬁn-embedded tissue from whole tissue sections.
zDetermined using TMA sections.
Classiﬁcation of Urothelial Carcinomashowed a labeling pattern similar to CCNB1 but with less
pronounced stratiﬁcation, conﬁrming that most of the
proliferation in UroA tumors occurs in the basal and
suprabasal cell layers.
KRT20 and UPK3 expression is restricted to the most
luminal cells in normal urothelium. However, KRT20
showed aberrant expression, localized to the tumor interior in
56% of tumors and to UPK3 in 35% of tumors. Only two
tumors (2%) showed KRT20 expression reminiscent of
normal urothelium. UPK3 expression in the apical membrane
of the most luminal cells was noted in 44% of tumors.
UroB Tumors
About half of the UroB tumors were muscle-invasive.
Eleven tumors demonstrated urothelial-like histologic
characteristics, and ﬁve tumors showed histologic signs of
squamous differentiation (Table 2). Similar to UroA tumors,
FGFR3 and CCND1 were expressed in 80% and 90% of
tumors, respectively, and TP63 was expressed in most
(>70%) cells in 80% of UroB tumors. KRT5 expression
was restricted to the basal cell layer in only two tumors
(10%), compared with 49% in UroA tumors (P < 0.002).
KRT14 was expressed in 30% of UroB tumors, compared
with 9% of UroA tumors (P < 0.01) (Figure 2B) and was
conﬁned to the basal cell layer when expressed. There was
no major difference in cadherin expression between UroA
and UroB tumors (Figure 3). Of 13 tumors that could be
evaluated for CCNB1, basal or suprabasal expression was
observed in 9 and in all cell layers in 4. MKI67 exhibited
a similar expression pattern. However, compared with UroA
tumors, UroB tumors demonstrated a signiﬁcantly larger
fraction of CCNB1þ and MKI67þ cells, indicating a higherThe American Journal of Pathology - ajp.amjpathol.orgproliferation index (Figure 4). KRT20 showed aberrant
expression in 47% of UroB tumors and was completely
negative in the remaining tumors. UPK3 expression was
absent in 80% of tumors.
SCCL Tumors
Most SCCL tumors were muscle-invasive, of high grade,
and showed various invasive growth patterns (Table 2).
Morphologic signs of squamous differentiation were noted
in 11 tumors (44%). Strong membrane DSC2/3 staining,
a marker for squamous differentiation, was noted in 67% of
SCCL tumors, compared with 7% of UroA and 30% of
UroB tumors (Figure 5A). FGFR3 positivity was observed
in 6 of 25 tumors, of which 3 showed expression close to the
detection level. Moreover, TP63 expression was observed in
signiﬁcantly fewer SCCL tumors compared with UroA and
UroB tumors (P < 3  106). Similarly, CCND1 was
negative or showed low expression in 84% of SCCL tumors
(Figure 5A). In contrast, EGFR expression was stronger
than in UroA tumors (P Z 8  104), noted in 96% of
SCCL tumors, and was not restricted to the basal cell layers
as in UroA tumors (Figures 3 and 5A).
SCCL tumors showed strong KRT5 expression
throughout the tumor parenchyma in 92% of cases. Of
importance, stroma-adjacent cells did not show stronger
KRT5 expression when compared with cells not in contact
with stroma (Figure 5A). KRT14 and KRT6, not normally
expressed in the urothelium or in the other subtypes of
urothelial carcinoma, showed expression in 76% and 24%
of tumors, respectively. In most positive tumors, KRT14
expression was moderate to strong and not limited to
stroma-adjacent cells. KRT20 positivity was noted in only 3685
Figure 2 Examples of IHC results for UroA tumors (A) and UroB tumors (B). Scale bars: 100 mm.
Sjödahl et altumors, and UPK3 in 10 of 25 tumors, all with aberrant
expression patterns. CCNB1 and MKI67 expression was
observed throughout the tumor parenchyma, indicating that
proliferation was not restricted to stroma-adjacent cells
(Figure 5A). CCNB1 and MKI67 expression was signiﬁ-
cantly higher in SCCL tumors than in UroB tumors, indi-
cating high proliferative activity (Figure 4). E-Cad
expression was completely absent in 5 of 24 SCCL tumors
and was signiﬁcantly lower than in UroA and UroB tumors
(P Z 3  107). In contrast, CDH3 (P-Cad) showed
signiﬁcantly stronger staining (P Z 106) in SCCL
compared with UroA and UroB tumors and all through the
tumor parenchyma (Figurse 3 and 5A). Only 2 of 25 SCCL
tumors (8%) showed CDH3 (P-Cad) expression restricted to
cells at the tumor-stroma interface, compared with 50% to
60% of UroA or UroB tumors.
GU Tumors
GU tumors were typically high grade (G3) and T1 or
muscle-invasive (Table 2). Half showed an invasive growth
pattern, and only six (9%) exhibited urothelial-like histo-
logic features. Signs of glandular differentiation were
observed in the GU subtype only (Table 2). GU tumors were686negative or showed low intensity for FGFR3 (Figure 3 and
Figure 5B). Similarly, most tumors (63%) were negative for
CCND1 expression (Figure 3), and when detected, expres-
sion was lower than in UroA and UroB tumors (PZ 0.007)
and was observed throughout the tumor parenchyma. TP63
expression was absent in 22% of GU tumors, and when
positive, only 35% showed labeling of most of the cells
(>70%), compared with 95% in UroA tumors (P Z 1 
1019). Hence, low FGFR3, CCND1, and TP63 expression
is a shared feature of GU tumors. Similarly, EGFR
expression was signiﬁcantly lower than in SCCL tumors
(P Z 0.001) (Figure 3). In contrast, GU tumors exhibited
higher ERBB2 expression than did SCCL (P Z 3.1 
107), UroA (P Z 2.4  105), and UroB (P Z 0.0017)
tumors (Figure 3). The vast majority of GU tumors were
KRT5 and KRT14 (Figure 3), and when detected,
expression was noted in isolated or small clusters of cells.
KRT6 was not expressed in any tumors. Aberrant KRT20
and UPK3 were, however, frequently observed, in 72% and
51% of tumors, respectively. Similar to SCCL tumors, GU
tumors showed high proliferative activity (Figure 4), with
no stratiﬁcation of CCNB1þ and MKI67þ cells (Figure 5B).
In contract to SCCL tumors, GU tumors demonstrated lowajp.amjpathol.org - The American Journal of Pathology
Figure 3 Proportional expression plots. Distribution of expression
levels for individual markers within each tumor subtype. Each box is
proportional to the fraction of tumors showing a TCS at the indicated level.
Maximum TCSZ 3, minimum TCSZ 0, and sum of box areas for each tumor
subtype Z 1.
Figure 4 Boxplots showing the fractions of cells positive for prolifer-
ation markers CCNB1 and MKI67 in the tumor subtypes.
Classiﬁcation of Urothelial CarcinomaCDH3 (P-Cad) but high CDH1 (E-Cad) expression
(Figure 3). IHC results for all molecular subtypes are
summarized in Figure 6.
Urothelial CarcinomaeSpeciﬁc Genomic Circuits Are
Also Detected at the Protein Level
By combining information on genomic alterations and
mRNA gene expression, we recently deﬁned two genomic
circuits operative in urothelial carcinoma.7 One circuit,
FGFR3/CCND1, was deﬁned in part by high FGFR3 andThe American Journal of Pathology - ajp.amjpathol.orgCCND1 but low CDKN2A (p16) expression. The latter was
frequently associated with homozygous deletions of the
CDKN2A gene.7 The second circuit, E2F3/RB1, was deﬁned
in part by E2F3 genomic ampliﬁcations and high expres-
sion, RB1 deletions and low expression, and high CDKN2A
(p16) expression. Using available IHC data, we calculated
a score for each of the two circuits assigned to each case
(see Material and Methods). The two circuits were also
detected at the protein level, and the FGFR3/CCDN1 circuit
was operative in UroA and UroB tumors, whereas the E2F3/
RB1 circuit was operative in GU tumors, SCCL being
unassigned (Figure 1D). These results stress the close bio-
logical relationship between UroA and UroB tumors.
Molecular Pathologic Classiﬁcation
We then constructed a tumor classiﬁer using the most
informative IHC, histologic, and morphologic variables.
Using only four variables (urothelial-like histologic features,
pathologic grade, CCNB1 >17% positive cells, and KRT5
tumor cell score >0.57), the original whole genomewide
gene expression classiﬁcation into UroA, UroB, SCCL, and
GU tumors was reproduced with an overall accuracy of 0.88
and with excellent sensitivity and positive prediction values
(Supplemental Figure S2 and Table 3). Attempts to subdi-
vide the urobasal subtype into UroA and UroB were made;
however, no acceptable division was obtained using the
available markers. Of the 18 UroB tumors included in the
analysis, 11 were classiﬁed as urobasal, 5 as SCCL, and 2 as
GU. In agreement with good classiﬁcation accuracy, the
urobasal group was identiﬁed as associated with a good
prognosis, the GU group with an intermediate outcome, and
the SCCL with an unfavorable prognosis, using disease-
speciﬁc survival as an endpoint and Kaplan-Meier analysis
(PZ 4  107) (Figure 7), in full accordance with previous
results obtained with whole genome gene expression
analysis.4
Discussion
In the present investigation we show that the four molecular
subtypes of urothelial carcinoma, formerly suggested by
whole genome gene expression analysis, demonstrate687
Figure 5 Examples of IHC results for SCCL (A) and GU (B) tumors. Scale bar Z 100 mm.
Sjödahl et aldistinct features at the molecular pathologic level. The
inﬁltrated group of tumors was omitted from the present
analyses because this group shows a high content of inﬁl-
trating immunologic cells4 and thus does not represent
a phenotype intrinsic to the tumor cells. The relationship
between tumor molecular subtype and inﬁltrating immu-
nologic cells is discussed elsewhere (Sjödahl et al, unpub-
lished results). Marker genes were selected on the basis of
the mRNA expression pattern in the context of the
molecular subtypes UroA, UroB, SCCL, and GU. To
facilitate an integrated molecular pathologic analysis, the
marker genes were selected to include different aspects of
cellular function such as cell cycle activity (CCNB1 and
MKI67), cell-cell interactions (E-Cad, N-Cad, P-Cad, and
DSC2/3), cellular architecture (KRT5, KRT6, and KRT14),
and tyrosine kinase receptors (FGFR3, ERBB2, and
EGFR). We next classiﬁed individual tumors with high
accuracy into the three major molecular subtypes using
a combination of only two IHC markers, urothelial-like
histologic ﬁndings and pathologic grade. This makes the
classiﬁcation system easy to implement in the standard
pathologic evaluation of urothelial carcinoma. Survival
analyses showed that this classiﬁcation system successfully688reproduced our previous results obtained using mRNA
gene expression arrays.
UroA tumors showed a labeling pattern reminiscent of
normal urothelium for several markers. KRT5, CDH3 (P-
Cad), and EGFR showed distinct labeling of cells adjacent
to the basal membrane, thus differentiating the basal cell
layers from the remaining tumor cells. UroA also showed
extended and smooth stromal interfaces, indicating a main-
tained tumor-stroma hierarchical organization; eg, pali-
sading of basal cells was frequently seen. Expression of
TP63, involved in epithelial stratiﬁcation, in stroma-
adjacent cells and throughout the tumor parenchyma
except for the most luminal cells is compatible with what is
observed in normal urothelium. Cell proliferation, as
determined by CCNB1 and MKI67, was primarily detected
adjacent to the stroma, suggesting possible dependence of
the basal membrane for proliferation. Indeed, CCNB1-
labeled cells were observed protruding from and
frequently in contact with the tumor-stroma interface.
CCND1, which also is a driver of the cell cycle, showed
suprabasal labeling that extended into the tumor paren-
chyma, sometimes including all tumor cells, thus producing
an overall stronger CCND1 staining pattern than observedajp.amjpathol.org - The American Journal of Pathology
Figure 6 Schema of IHC results for selected markers. Normal indicates
expression pattern in normal urothelium. Urobasal tumors are divided into
UroA and UroB and are schematically drawn with a basal cell layer, inter-
mediate cells, and luminal cells. Dark shading indicates strong expression.
For CCNB1, single cells protruding from the tumor-stroma interface are
indicated by lines, and positive cells within the tumor parenchyma as dots.
Centered shading for KRT20 indicates aberrant expression frequently seen
in the center of the tumor parenchyma.
Table 3 Results of IHC/Histopathology Classiﬁcation
Variable Uro (IHC*) SCCL (IHC) GU (IHC) Sensitivityy
UroA/UroB (GEXz) 115 6 11 0.87
SCCL (GEX) 2 22 1 0.88
GU (GEX) 5 1 62 0.91
PPVx 0.94 0.76 0.84
*Classiﬁcation according to IHC/histopathology classiﬁer using leave-
one-out cross-validation.
ySensitivity of IHC/histopathology classiﬁer.
zClassiﬁcation according to whole genome gene expression.4
xPPV for IHC/histopathology classiﬁer.
PPV, positive predictive value.
Classiﬁcation of Urothelial Carcinomain normal urothelium. Emerging ﬁndings indicate that UroA
tumors are driven by increased proliferative activity of cells
in close proximity to the stroma/basal membrane boundary,
thus resembling the pattern of proliferation and cell turnover
observed in normal urothelium.
In contrast, the differentiation markers KRT20 and UPK3
frequently showed aberrant expression. In particular,
KRT20 expression was often observed in the interior of the
tumor parenchyma, supporting the observation by He et al12
that KRT20 may be aberrantly expressed within the tumor
parenchyma as a function of distance from the stromal
compartment. Luminal cells, when present in cores,
frequently shared morphologic features with umbrella cells,
even when KRT20 or UPK3. These ﬁndings suggest
a compromised differentiation process in UroA with only
parts of the original differentiation program in operation.The American Journal of Pathology - ajp.amjpathol.orgHowever, in large tumors with many cell layers, an aberrant
differentiation program may be activated within the tumor
parenchyma.
SCCL tumors showed staining patterns in strong
contrast to those of UroA tumors. KRT5, CDH3 (P-Cad),
and EGFR expression, limited to the basal cell layer in
UroA tumors, in SCCL tumors was detected throughout
the tumor parenchyma and with higher intensity. Conse-
quently, SCCL cells seem to have acquired properties
similar to those of basal cells in normal urothelium and
could thus be denoted as basal-like. Inasmuch as the SCCL
class of tumors was distinguished by being KRT14þ,
KRT5þ, and KRT20, this group conforms to the basal
category of tumors described by Volkmer et al13 and also
by Chan et al14 However, in contrast to basal cells of UroA
tumors, the basal-like character of SCCL cells is inde-
pendent of direct contact with stroma. Furthermore, the
SCCL subtype of urothelial cancer shows an IHC marker
proﬁle similar to the basal-like phenotype in breast carci-
nomas.15 This again stresses the similarity of SCCL tumors
to undifferentiated basal-like cells.16 Proliferation, as
detected by CCNB1 and MKI67, was substantially
stronger than in UroA tumors, was observed throughout
the tumor parenchyma, and was not topologically con-
strained as in UroA tumors.
Tumor cell proliferation in GU tumors was noted
throughout the tumor parenchyma. However, in contrast to
SCCL tumors, GU tumors did not express KRT5, KRT14,
or KRT6 and showed high CDH1 (E-Cad) but low CDH3
(P-Cad) expression. Our results are in agreement with
previous analyses that related cadherin expression pattern to
tumor stage and grade.17 GU tumors also differed distinctly
from UroA tumors by showing absence of or strongly
deranged urothelial-like stratiﬁcation. A characteristic fea-
ture of many GU tumors was lack of or low expression of
most markers in the panel, with the exception of ERRB2,
CCNB1, MKI67, and CDH1 (E-Cad). Hence, GU tumors
correspond to undifferentiated high-grade cells with a strong
proliferative potential. A critical difference between UroA
tumors and SCCL and GU tumors seems to be the apparent
independence of cell proliferation from the stroma/basal
membrane in the latter two. We have previously shown that
the change between UroA to SCCL and GU is accompanied689
Figure 7 Kaplan-Meier plot of disease-speciﬁc survival. Tumors are
stratiﬁed by molecular subtype as determined by the IHC/histology clas-
siﬁer. Classiﬁcation was obtained through leave-one-out cross-validation.
Sjödahl et alby a transition from high expression of early cell cycle
genes, in particular CCND1, to high expression of late cell
cycle genes, eg, CCNE1.4 Hence, independence of prolif-
eration from the stroma/basal membrane may be a decisive
shift in the progression of urothelial carcinoma.
UroB and UroA tumors share high expression of FGFR3,
CCND1, and TP63 and a high FGFR3 mutation frequency.4
However, UroB tumors differ from UroA tumors in that
they exhibit higher fractions of KRT5-expressing cells not
necessarily restricted to the basal and suprabasal cell layers,
a higher fraction KRT14þ tumors, higher numbers of
CCNB1þ and MKI67þ cells, and lower CDKN2A (p16)
expression. Most important, half of the UroB tumors are
muscle-invasive, which suggests that UroB tumors are
a molecularly evolved version of UroA tumors. UroB
tumors are most likely represented among the FGFR3
mutated and CDKN2A homozygous deleted tumors with
a bad prognosis described by Rebouissou et al18 and the
muscle-invasive tumors that have retained TP63 expression
described by Urist et al.19
We have recently identiﬁed two genomic circuits opera-
tive in urothelial carcinoma, the FGFR3/CCND1 and E2F3/
RB1 circuits.11 When translated into IHC markers, the
FGFR3/CCND1 circuit produces high scores and the E2F3/
RB1 circuit low scores in both UroA and UroB tumors,
whereas the opposite is noted in GU tumors. These ﬁndings
emphasize the distinct natures of UroA, UroB, and GU
tumors and the close relationship between UroA and UroB
tumors. Furthermore, the four subtypes show distinct
expression of key receptor tyrosine kinases. UroA and UroB
tumors show strong FGFR3 and moderate to low ERBB2
and EGFR expression. In contrast, SCCL tumors show
almost absent FGFR3 and ERBB2 but strong EGFR
expression, and GU tumors show almost absent FGFR3 and690EGFR but strong ERBB2 expression. Together this iden-
tiﬁes UroA and UroB, GU, and SSCL as three basic
molecular pathologic subtypes of urothelial carcinoma.
In breast cancer, gene expression and IHC-based classiﬁ-
cation systems have been developed in parallel and have
subsequently been successfully reconciled. The major
intrinsic molecular subtypes of breast cancer were ﬁrst iden-
tiﬁed by gene expression proﬁling20 and later were translated
into three main IHC-based subtypes using estrogen receptor,
progesterone receptor, and HER2 antibodies. Additional IHC
markers have been used to identify the molecular subtypes in
greater detail: MKI67 to differentiate luminal A from luminal
B and KRT5/6 and EGFR to identify the basal-like subtype
among the estrogen receptor, progesterone receptor, and
HER2 triple-negative tumors, reviewed by Blows et al.21 To
facilitate the translation of our suggested urothelial carcinoma
molecular taxonomy into clinical practice, we used results for
all 20 IHC markers, pathologic data (grade and stage), and
information about growth pattern to establish a simple clas-
siﬁcation system. Selection of classiﬁer variables was unsu-
pervised, and care was taken to limit the number of markers.
The ﬁnal classiﬁer arrived at included information on CCNB1
and KRT5 staining, pathologic grade, and urothelial-like
growth pattern. Using these four markers, the three major
molecular subtypes of urothelial cancer could be predicted
with high ﬁdelity. Furthermore, the IHC and histopathologic
subtypes correspond to distinct groups with respect to prog-
nosis. The small UroB group could not be identiﬁed as
a separate group by using the selected set of markers. The
difﬁculty in identiﬁcation of the UroB subtype using the IHC
or histologic classiﬁer most likely results because the UroB
group shares features with both the GU and SCCL subtypes,
eg, invasiveness and high proliferation rate, and with UroA,
eg, high FGFR3 expression and stratiﬁed KRT5 expression.
Consequently, no single variable can easily be attributed to
the class of UroB tumors. As a result, about half of UroB
tumors were classiﬁed as low risk urobasal and half as high-
risk GU or SCCL tumors. It must be stressed, however, that
TMA was used in the present investigation and that better
differentiation may have been attained using whole tissue
sections. Irrespective, we noted that assessment of pathologic
stage was not necessary to obtain excellent classiﬁcation
results. We argue that our suggested mRNA-based molecular
taxonomy and the present IHC- and histopathology-based
classiﬁcation systems are promising tools for understanding
urothelial cancer biology and for future bladder cancer
management. We do, however, stress the importance of
classiﬁer validation in truly independent data with long-term
follow-up and analysis via both IHC and histopathology and
by genomewide gene expression.Acknowledgment
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